Cholesterol Goal Attainment Rate and Its Associated Factors Among Dyslipidemic Patients on Lipid-lowering Drug Therapy in Korea
CRESENDO
1 other identifier
observational
4,950
1 country
20
Brief Summary
This is a multi-centre, cross-sectional, chart review study to investigate cholesterol goal attainment rates defined by modified NCEP-ATP III guidelines and define its possible determinants among Korean dyslipidemic patients
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Aug 2011
Shorter than P25 for all trials
20 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
June 7, 2011
CompletedFirst Posted
Study publicly available on registry
June 14, 2011
CompletedStudy Start
First participant enrolled
August 1, 2011
CompletedPrimary Completion
Last participant's last visit for primary outcome
October 1, 2011
CompletedStudy Completion
Last participant's last visit for all outcomes
October 1, 2011
CompletedDecember 22, 2011
December 1, 2011
2 months
June 7, 2011
December 21, 2011
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Cholesterol goal attainment rate according to NCEP-ATP III guideline
Once, at enrollment
Secondary Outcomes (2)
Factors for cholesterol goal achievement: Age, Family history, smoking history, waist circumstance, etc.
Once, at enrollment
Cholesterol goal attainment rate related to CHD or disease history
Once, at enrollment
Study Arms (1)
Dyslipidemia
Eligibility Criteria
Primary Care
You may qualify if:
- Patient who has a dyslipidemia with a lipid profile result within 3 months
- Patient who has a dyslipidemia without change of lipid lowering drug dosage during 3 months after lipid profile test.
You may not qualify if:
- Patient who involved in this study previously.
- Patient who participated in other clinical study with study drug within 90 days.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- AstraZenecalead
Study Sites (20)
Research Site
Busan, Busan, South Korea
Research Site
Cheonan, Chungcheongnam-do, South Korea
Research Site
Tae, Chungcheongnam-do, South Korea
Research Site
Chuncheon, Gangwon-do, South Korea
Research Site
Gwangju, Gwangju, South Korea
Research Site
Anyang-si, Gyeonggi-do, South Korea
Research Site
Bucheon-si, Gyeonggi-do, South Korea
Research Site
Bundang, Gyeonggi-do, South Korea
Research Site
Goyang-si, Gyeonggi-do, South Korea
Research Site
Guri-si, Gyeonggi-do, South Korea
Research Site
Uijeongbu-si, Gyeonggi-do, South Korea
Research Site
Incheon, Incheon, South Korea
Research Site
Gwangju, Jeollabuk-do, South Korea
Research Site
Iksan, Jeollabuk-do, South Korea
Research Site
Daegu, Kyeongsangbuk-do, South Korea
Research Site
Deagu, Kyeongsangbuk-do, South Korea
Research Site
Busan, Kyeongsangnam-do, South Korea
Research Site
Changwon, Kyeongsangnam-do, South Korea
Research Site
Cheongju-si, North Chungcheong, South Korea
Research Site
Seoul, Seoul, South Korea
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Jeong Ui Park
Samsung Medical Center
- PRINCIPAL INVESTIGATOR
Jong sung Kim
Seoul National University Hospital
- PRINCIPAL INVESTIGATOR
Sung woo Park
Kangbuk Samsung Hospital
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
June 7, 2011
First Posted
June 14, 2011
Study Start
August 1, 2011
Primary Completion
October 1, 2011
Study Completion
October 1, 2011
Last Updated
December 22, 2011
Record last verified: 2011-12